The newly-formed Angionetics, Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group, is an angiogenesis gene therapy company focused on the development and commercialization of novel DNA-based therapeutics that are designed to promote the heart’s innate natural capacity to modulate the formation and growth of cardiac microvascular circulation to enhance blood flow (perfusion) in patients with a variety of ischemia-driven disease conditions and refractory angina and myocardial ischemia due to cardiac microvascular insufficiency (CMI), and other cardiovascular disease conditions.  For more information, visit the company’s website at www.angionetics.com or www.cardiumthx.com